ATHX Stock - Athersys Inc.

ATHX Stock Chart

ATHX Profile

Athersys, Inc., a pioneering biotechnology firm, is dedicated to advancing research and development in the realm of regenerative medicine. The company focuses on clinical programs aimed at treating a broad spectrum of medical conditions, including neurological disorders, cardiovascular diseases, inflammatory ailments, and pulmonary conditions. Central to its portfolio is the MultiStem cell therapy, an innovative allogeneic stem cell product currently undergoing Phase III clinical trials. This therapy shows promise in addressing neurological damage from ischemic stroke, acute respiratory distress syndrome, trauma complications, and offering support for hematopoietic stem cell transplants, among other indications.

In addition to its clinical initiatives, Athersys is actively developing MultiStem cell therapy for veterinary applications, targeting serious conditions in animals with significant unmet medical needs. The company has established key partnerships and licensing agreements to further its research and commercialization efforts. Collaborations with Healios K.K. are focused on advancing MultiStem therapies for ischemic stroke, acute respiratory distress syndrome, and various ophthalmological, liver, kidney, pancreas, and intestinal tissue diseases. Athersys also collaborates with the University of Minnesota to explore and expand the MultiStem cell therapy platform.

Founded in 1995 and headquartered in Cleveland, Ohio, Athersys, Inc. remains committed to leveraging its cutting-edge technologies and strategic partnerships to deliver innovative regenerative solutions. With a robust pipeline and a strong foundation in scientific research, the company continues to pave the way for transformative therapies that aim to improve patient outcomes and address critical medical needs globally.

ATHX Revenue Chart

ATHX Earnings

Analyst Ratings